Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Patient comfort in AI-driven healthcare linked to familiarity, finds GlobalData

As the healthcare landscape undergoes transformation due to factors like aging populations, rising chronic diseases, and shifts in lifestyle choices, technology, particularly artificial intelligence (AI), is playing an increasingly vital role. A recent survey highlights how patients’ familiarity with AI significantly influences their comfort level when considering healthcare facilities utilizing this technology, according to GlobalData, […]
Read more

Steatosis-associated fibrosis estimator algorithm offers hope for early detection and management of NAFLD/NASH, says GlobalData

A novel diagnostic tool, the steatosis-associated fibrosis estimator (SAFE) algorithm, may revolutionize the early detection of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). NAFLD, a common liver condition, often remains undiagnosed until advanced stages. The SAFE algorithm offers promising potential to enhance patient identification, enabling proactive healthcare interventions and alleviating the burden on […]
Read more

Novo Nordisk Wegovy’s NHS access marks milestone in obesity treatment, but challenges remain, says GlobalData

Novo Nordisk‘s obesity medication Wegovy (semaglutide) will soon be accessible through the National Health Service (NHS) in England, albeit with limited supply. To maintain controlled distribution, the National Institute for Health and Clinical Excellence (NICE) will implement eligibility criteria, focusing on patients with comorbidities and specific BMI ranges. Although expected to become a leading obesity […]
Read more

Intercept acquisition by Alfasigma reflects NASH failure, says GlobalData

The acquisition of Intercept Pharmaceuticals by the Italian pharmaceutical company Alfasigma became inevitable due to the failed development of Intercept’s flagship asset, obeticholic acid, as a treatment for non-alcoholic steatohepatitis (NASH). With no advanced assets left in its pipeline and rapidly declining share prices, Intercept had a compelling reason to pursue acquisition, says GlobalData, a […]
Read more

GlobalData highlights importance of World Contraception Day in promoting patient education and choice in female contraception

September 26 marks World Contraception Day across the world. An essential gap in the realm of female contraception revolves around educating patients about the diverse contraceptive options at their disposal. World Contraception Day plays a vital role in promoting awareness regarding available contraceptive methods, empowering young individuals to make well-informed decisions regarding their sexual health, […]
Read more

New generics in idiopathic pulmonary fibrosis space will provide more access to patients, says GlobalData

The idiopathic pulmonary fibrosis (IPF) market is underserved with just two licensed pharmaceutical treatments which are available globally, Roche’s Esbriet/Pirespa (pirfenidone) and Boehringer Ingelheim’s (BI) Ofev (nintedanib), which were both approved by the FDA in 2014. Since the patent expiration of Esbriet in 2021, new generic versions have begun entering the IPF space providing more […]
Read more

Forxiga looking for expanded approval to differentiate in HF space fails in DICTATE-AHF trial, says GlobalData

At the 2023 European Society of Cardiology (ESC) Congress, study results found that early initiation of Forxiga (dapagliflozin) failed to improve diuretic efficiency in hospitalized patients with acute decompensated heart failure (ADHF). Specifically, the DICTATE-AHF trial set out to evaluate whether early initiation of Forxiga within the first day of hospitalization could optimize guideline directed […]
Read more

Relmada Therapeutics antidepressant REL-1017 shows promise but requires additional data, opines GlobalData

Following the news that Relmada Therapeutics’ antidepressant REL-1017 demonstrated rapid and sustained therapeutic effects in an open label, registrational Phase III trial (NCT04855760); Philippa Salter, Senior Neurology Analyst at GlobalData, offers her view: “Whilst these positive results are important for Relmada Therapeutics in demonstrating the efficacy of REL-1017 as an adjunctive therapy for major depressive […]
Read more

Genexine’s GX-E4 holds potential to change renal anemia treatment landscape in APAC, says GlobalData

Genexine recently released positive interim findings from the Phase III clinical trial of GX-E4 (Efepoetin alfa) for anemia induced by chronic kidney disease (CKD) or renal anemia in non-dialysis patients. Interim analysis confirms GX-E4 is non-inferior to Roche’s Mircera, a third-generation long-acting anemia treatment. As it advances towards regulatory submission in various APAC countries, Genexine […]
Read more

Eli Lilly’s Mounjaro to become leading GLP-1 therapy for type 2 diabetes in NHS in UK, says GlobalData

Eli Lilly received approval for its dual glucagon-like peptide-1 receptor agonist (GLP-1)/gastric inhibitor polypeptide receptor agonist (GIP) therapy Mounjaro (tirzepatide) in August 2023 for use as a new treatment option for patients in England with type 2 diabetes (T2D), in cases where the existing treatment management options are insufficient. With the recent clinical data that […]
Read more

Fungal Disease Awareness Week: Novel antifungals essential to tackle antifungal resistance, says GlobalData

This week (18-22 September) marks Fungal Disease Awareness Week (FDAW) in the US, an annual event in which the Centers for Disease Control and Prevention (CDC) and partners promote activities and outreach that encourage everyone to “Think Fungus”. This often-underestimated health burden is the focus of webinars and interactive events designed to encourage awareness and […]
Read more

CureVac highlights shift to mRNA technology in seasonal influenza vaccine development, says GlobalData

CureVac, in collaboration with GSK, recently announced the advancement of its multivalent, modified mRNA seasonal influenza vaccine candidate into Phase II clinical trials. The interim Phase I results reported positive safety and immunogenicity data, citing observed humoral responses in support of the selection of a vaccine candidate to proceed into Phase II testing. CureVac’s utilization […]
Read more

Major unmet needs plague classification and treatment of myasthenia gravis, says GlobalData

Myasthenia gravis (MG) is an autoimmune and neuromuscular disease characterized by muscle weakness and fatigue. Currently, most of the first-line treatment options are off-label symptomatic therapies, mainly due to their affordability and accessibility, while disease modifying therapies (DMTs) are typically reserved for refractory patients diagnosed with class II-V MG. As a result, major unmet needs […]
Read more

World Sepsis Day 2023: GlobalData highlights promise of new treatments

World Sepsis Day is commemorated on the 13th of September every year to raise awareness about this life-threatening condition, resulting in at least 11 million deaths occurring globally each year. Over 7,000 facilities and organizations around the world are expected to take part in World Sepsis Day, hosting events such as provision of medical education, […]
Read more
1 … 30 31 32 33 34 … 110